Evidence map›Paper›PMID 14565848›Full record

ArticleBMC microbiology2003

Type III secretion proteins PcrV and PcrG from Pseudomonas aeruginosa form a 1:1 complex through high affinity interactions.

Max Nanao, Sylvie Ricard-Blum, Anne Marie Di Guilmi, David Lemaire, David Lascoux, Jacqueline Chabert, Ina Attree, Andréa Dessen

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. The small non-coding RNA sRNA102 regulatesFrontiers in cellular and infection microbiology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Effects of Glycyrrhizin on Multi-Drug ResistantPathogens (Basel, Switzerland) · 2020
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Topical antimicrobials for burn infections - an update.Recent patents on anti-infective drug discovery · 2013
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Max NanaoInstitut de Biologie Structurale (CNRS/CEA/UJF), 41 rue Jules Horowitz, 38027 Grenoble, France. mnanao@ibs.fr
Sylvie Ricard-Blum
Anne Marie Di Guilmi
David Lemaire
David Lascoux
Jacqueline Chabert
Ina Attree
Andréa Dessen
Université Joseph Fourier · FRUniversité Grenoble Alpes · FRCEA Grenoble · FRCommissariat à l'Énergie Atomique et aux Énergies Alternatives · FRInstitut de Biologie Structurale · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPseudomonas aeruginosa, an increasingly prevalent opportunistic pathogen, utilizes a type III secretion system for injection of toxins into host cells in order to initiate infection. A crucial component of this system is PcrV, which is essential for cytotoxicity and is found both within the bacterial cytoplasm and localized extracellularly, suggesting that it may play more than one role in Pseudomonas infectivity. LcrV, the homolog of PcrV in Yersinia, has been proposed to participate in effector secretion regulation by interacting with LcrG, which may act as a secretion blocker. Although PcrV also recognizes PcrG within the bacterial cytoplasm, the roles played by the two proteins in type III secretion in Pseudomonas may be different from the ones suggested for their Yersinia counterparts.

resultsIn this work, we demonstrate by native mass spectrometry that PcrV and PcrG expressed and purified from E. coli form a 1:1 complex in vitro. Circular dichroism results indicate that PcrG is highly unstable in the absence of PcrV; in contrast, both PcrV alone and the PcrV:PcrG complex have high structural integrity. Surface plasmon resonance measurements show that PcrV interacts with PcrG with nanomolar affinity (15.6 nM) and rapid kinetics, an observation which is valid both for the full-length form of PcrG (residues 1-98) as well as a form which lacks the C-terminal 24 residues, which are predicted to have low secondary structure content.

conclusionsPcrV is a crucial component of the type III secretion system of Pseudomonas, but the way in which it participates in toxin secretion is not understood. Here we have characterized the interaction between PcrV and PcrG in vitro, and shown that PcrG is highly unstable. However, it associates readily with PcrV through a region located within its first 74 amino acids to form a high affinity complex. The fact that PcrV associates and dissociates quickly from an unstable molecule points to the transient nature of a PcrV:PcrG complex. These results are in agreement with analyses from pcrV deletion mutants which suggest that PcrV:PcrG may play a different role in effector secretion than the one described for the LcrV:LcrG complex in Yersinia.

Indexed as

Amino Acid SequenceAntigens, BacterialBacterial ProteinsBacterial ToxinsMacromolecular SubstancesMolecular Sequence DataPore Forming Cytotoxic ProteinsPseudomonas aeruginosaSequence AlignmentAntigens, Bacterialantigen V, PseudomonasBacterial ProteinsBacterial ToxinsMacromolecular SubstancesPore Forming Cytotoxic Proteins

Identifiers

PMID14565848
PMCPMC270082
OpenAlexW1877903228

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.